Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 23, Issue 16, 2005, Pages 3819-3829

  Sorror, Mohamed L ^a   Maris, Michael B ^a   Sandmaier, Brenda M ^a   Storer, Barry E ^a   Stuart, Monic J ^a   Hegenbart, Ute ^a   Agura, Edward ^a   Chauncey, Thomas R ^a   Leis, Jose ^a   Pulsipher, Michael ^a   McSweeney, Peter ^a   Radich, Jerald P ^a   Bredeson, Christopher ^a   Bruno, Benedetto ^a   Langston, Amelia ^a   Loken, Michael R ^a   Al Ali, Haifa ^a   Blume, Karl G ^a   Storb, Rainer ^a   Maloney, David G ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; VIDARABINE;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CELL TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; NONMYELOABLATIVE CONDITIONING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; WHOLE BODY RADIATION; AUTOTRANSPLANTATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REMISSION; SALVAGE THERAPY; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 20544465644     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.569     Document Type: Article

References (67)

1. Linet MS, Blattner WA: The epidemiology of chronic lymphocytic leukemia, in Pollack A, Catovsky D (eds): Chronic Lymphocytic Leukemia. Chur, Switzerland, Harwood Academic Publishers, 1988, pp 11-32
2. National Cancer Institute: SEER Cancer Statistics Review, 1975-2001. Bethesda, MD, National Cancer Institute, 2004
3. Dreger P, Montserrat E: Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 16:985-992, 2002
4. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757, 2000
5. Johnson S, Smith AG, Loffler H, et al: Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 347:1432-1438, 1996
6. Leporrier M, Chevret S, Cazin B, et al: Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98:2319-2325, 2001
7. O'Brien SM, Kantarjian HM, Cortes J, et al: Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19:1414-1420, 2001
8. Seymour JF, Robertson LE, O'Brien S, et al: Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: A basis for the use of myeloablative therapies. Leuk Lymphoma 18:493-496, 1995
9. Keating MJ, Flinn I, Jain V, et al: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 99:3554-3561, 2002
10. Weiss MA, Maslak PG, Jurcic JG, et al: Pentostatin and cyclophosphamide: An effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 21: 1278-1284, 2003
11. Garcia Manero G, O'Brien S, Cortes J, et al: Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia. Blood 98:633a, 2001 (part 1, abstr 2650)
12. Byrd JC, Peterson B, Piro L, et al: A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: Results from CALGB Study 9211. Leukemia 17: 323-327, 2003
13. Montillo M, Tedeschi A, O'Brien S, et al: Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 97: 114-120, 2003
14. Rai KR, Keating MJ, Coutre S, et al: Patients with refractory B-CLL and T-PLL treated with alemtuzumab (Campath) on a compassionate basis: A report on efficacy and safety of CAM 511 trial. Blood 100:802a, 2002 (part 1, abstr 3165)
15. O'Brien SM, Kantarjian H, Thomas DA, et al: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165-2170, 2001
16. Byrd JC, Murphy T, Howard RS, et al: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19: 2153-2164, 2001
17. Wierda W, O'Brien S, Faderl S, et al: Improved survival in patients with relapsed-refractory chronic lymphocytic leukemia (CLL) treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination. Blood 102:110a, 2003 (part 1, abstr 373)
18. Esteve J, Montserrat E, Dreger P, et al: Stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL): Outcome and prognostic factors after autologous and allogeneic transplants. Blood 98:482a, 2001 (part 1, abstr 2013)
19. Michallet M, Brand R, Dreger P, et al: Analysis of prognostic factors on the outcome of autologous and allogeneic stem cell transplantations (SCT) for chronic lymphocytic leukemia (CLL). Blood 98:859a-860a, 2001 (part 1, abstr 3568)
20. Milligan DW, Fernandes S, Dasgupta R, et al: Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 105: 397-404, 2005
21. Pavletic S, Khouri I, King R, et al: HLA-matched unrelated donor (MUD) bone marrow transplantation for B-cell chronic lymphocytic leukemia (results from the CLL Working Group, National Marrow Donor Program). Proc Am Soc Clin Oncol 18:4a, 2000 (abstr 8)
22. Pavletic ZS, Arrowsmith ER, Bierman PJ, et al: Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant 25:717-722, 2000
23. Doney KC, Chauncey T, Appelbaum FR: Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant 29:817-823, 2002
24. Michallet M, Archimbaud E, Bandini G, et al: HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia: European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med 124:311-315, 1996
25. Khouri IF, Keating MJ, Saliba RM, et al: Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 4:217-221, 2002
26. Storb R, Yu C, Wagner JL, et al: Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89: 3048-3054, 1997
27. Niederwieser D, Maris M, Shizuru JA, et al: Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101: 1620-1629, 2003
28. Maris MB, Niederwieser D, Sandmaier BM, et al: HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 102:2021-2030, 2003
29. McSweeney PA, Niederwieser D, Shizuru JA, et al: Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390-3400, 2001
30. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
31. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
32. Sorror ML, Maris MB, Storer B, et al: Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: Influence of pretransplant comorbidities. Blood 104:961-968, 2004
33. Petersdorf EW, Gooley TA, Anasetti C, et al: Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 92:3515-3520, 1998
34. Maloney DG, Molina AJ, Sahebi F, et al: Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102:3447-3454, 2003
35. Sullivan KM: Graft-versus-host disease, in Thomas ED, Blume KG, Forman SJ (eds): Hematopoietic Cell Transplantation (ed 2). Maiden, MA, Blackwell Sciences, 1999, pp 515-536
36. Diaconescu R, Flowers CR, Storer B, et al: Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors. Blood 104:1550-1558, 2004
37. Dumam DM, Anders KR, Fisher L, et al: Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y-chromosome-specific in situ hybridization assay. Blood 74:2220-2226, 1989
38. Ugozzoli L, Yam P, Petz LD, et al: Amplification by the polymerase chain reaction of hypervariable regions of the human genome for evaluation of chimerism after bone marrow transplantation. Blood 77:1607-1615, 1991
39. Wells DA, Sale GE, Shulman HM, et al: Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation. Am J Clin Pathol 110:84-94, 1998
40. Montserrat E: Treatment options in chronic lymphocytic leukemia. Hematol J 5:S2-S9, 2004 (suppl 1)
41. Oscier DG, Gardiner AC, Mould SJ, et al: Multivariate analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100:1177-1184, 2002
42. Kalil N, Cheson BD: Chronic lymphocytic leukemia. Oncologist 4:352-369, 1999
43. Khouri IF, Lee MS, Saliba RM, et al: Non-ablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: Impact of rituximab on immunomodulation and survival. Exp Hematol 32:28-35, 2004
44. Kolb HJ, Schmidt C, Barrett AJ, et al: Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103:767-776, 2004
45. Riddell SR, Berger C, Murata M, et al: The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev 17:153-162, 2003
46. Bleakley M, Riddell SR: Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 4:371-380, 2004
47. Dohner H, Stilgenbauer S, James MR, et al: 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 89:2516-2522, 1997
48. Dohner H, Fischer K, Bentz M, et al: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580-1589, 1995
49. Juliusson G, Oscier DG, Fitchett M, et al: Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 323:720-724, 1990
50. Dohner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000
51. Ghia P, Guida G, Stella S, et al: The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 101:1262-1269, 2003
52. Hamblin TJ, Orchard JA, Ibbotson RE, et al: CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99:1023-1029, 2002
53. Jabbour E, Keating MJ, Champlin RE, et al: Stem cell transplantation for chronic lymphocytic leukemia: Should not more patients get a transplant? Bone Marrow Transplant 34:289-297, 2004
54. H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999
55. Moreno C, Colomer D, Villamor N, et al: Allogeneic, but not autologous, stem-cell transplantation overcomes the negative impact of unmutated VH genes in patients with CLL. Blood 102:152a, 2003 (part 1, abstr 522)
56. Ritgen M, Stilgenbauer S, von Neuhoff N, et al: Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: Implications of minimal residual disease measurement with quantitative PCR. Blood 104:2600-2602, 2004
57. Orchard JA, Ibbotson RE, Davis Z, et al: ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363:105-111, 2004
58. Fukuda T, Boeckh M, Guthrie KA, et al: Invasive aspergillosis prior to allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 10:494-503, 2004
59. Fukuda T, Boeckh M, Carter RA, et al: Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 102:827-833, 2003
60. Junghanss C, Storb R, Maris MB, et al: Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation. Br J Haematol 123:662-670, 2003
61. Marr KA, Crippa F, Leisenring W, et al: Itraconazole versus fluconazole for prevention of fungal infections in allogeneic stem cell transplant patients. Blood 103:1527-1533, 2004
62. Boeckh M, Nichols WG: The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103:2003-2008, 2004
63. Boeckh M, Huang ML, Ferrenberg J, et al: Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 42:1142-1148, 2004
64. Boeckh M, Fries B, Nichols WG: Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation. Pediatr Transplant 8:19-27, 2004 (suppl 5)
65. Dreger P, Brand R, Hansz J, et al: Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 17:841-848, 2003
66. Schetelig J, Thiede C, Bornhauser M, et al: Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-plantation intensity conditioning and allogeneic stem-cell transplantation: The Cooperative German Transplant Study Group. J Clin Oncol 21:2747-2753, 2003
67. Morris E, Thomson K, Craddock C, et al: Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 104:3865-3871, 2004